Substituted Alkynylene Compounds Targeting EGFR and BCR Pathways

Solution Overview

Problem

Current cancer treatments, particularly chemotherapy, are limited and often come with significant side effects, necessitating the development of new anti-cancer agents that act through different mechanisms and pathways.

Innovation Solution

Development of novel substituted alkynylene derivatives and their pharmaceutical compositions, which can be used as anti-cancer agents, targeting various types of cancer, including lymphomas and leukemias, by inhibiting specific growth-promoting pathways such as EGFR signaling and BCR pathway components.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy is used to treat cancer, then cancer cell growth is inhibited, but significant side effects occur and treatment options are limited

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by developing novel substituted alkynylene compounds with modified chemical structures (formula I) that differ from conventional chemotherapy agents. These structural parameter changes enable the compounds to inhibit cancer cell growth through different mechanisms, specifically targeting growth-promoting pathways while reducing the harmful side effects associated with traditional chemotherapy

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention employs composite materials by creating complex substituted alkynylene compounds that combine multiple functional groups and structural elements (aryl, heteroaryl, cycloalkyl, heterocycloalkyl groups with various substituents). This composite molecular structure allows for targeted inhibition of cancer pathways while minimizing off-target effects that cause side effects

Inventive Principle:
Principle #40Composite materials

2Adaptability or versatility

If new anti-cancer agents are developed to act through different mechanisms, then treatment options are expanded and side effects are reduced, but the complexity of drug development increases

Engineering Contradiction:
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the complex drug development process into systematic stages: identifying target pathways (EGFR signaling, BCR pathway), designing specific molecular structures (formula I with defined substituents A, B, R1-R4, X, Y), synthesizing compounds, and evaluating anticancer activity. This segmented approach manages development complexity while expanding treatment options through mechanism-based classification

Inventive Principle:
Principle #1Segmentation

Data Source

PatentUS11633394B2Substituted alkynylene compounds as anticancer agents
Publication Date: 2023.04.25
  • US11633394B2 patent drawing
  • US11633394B2 patent drawing
  • US11633394B2 patent drawing

AI summary

The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.